Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Operating Margin (2016 - 2025)

IGC Pharma has reported Operating Margin over the past 16 years, most recently at 1517.8% for Q3 2025.

  • Quarterly Operating Margin fell 109062.0% to 1517.8% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 731.83% through Sep 2025, down 54112.0% year-over-year, with the annual reading at 585.84% for FY2025, 38286.0% down from the prior year.
  • Operating Margin was 1517.8% for Q3 2025 at IGC Pharma, down from 580.79% in the prior quarter.
  • Over five years, Operating Margin peaked at 4732.79% in Q1 2022 and troughed at 7764.29% in Q3 2021.
  • The 5-year median for Operating Margin is 880.88% (2024), against an average of 1173.41%.
  • Year-over-year, Operating Margin soared 817847bps in 2022 and then plummeted -716592bps in 2023.
  • A 5-year view of Operating Margin shows it stood at 1679.58% in 2021, then surged by 59bps to 686.14% in 2022, then plummeted by -114bps to 1469.61% in 2023, then soared by 50bps to 730.74% in 2024, then tumbled by -108bps to 1517.8% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Operating Margin are 1517.8% (Q3 2025), 580.79% (Q2 2025), and 427.88% (Q1 2025).